A Balanca1, A Even1, C Malot2, E Chartier-Kastler1,3,4, P Denys1,4, C Joussain5,6. 1. Neuro-Uro-Andrology Hospital Universitaire R.Poincare, AP-HP, 104 bvd R. Poincare, 92380, Garches, France. 2. Department of Sport Medicine and Readaptation, Hôpital Foch, 92150, Suresnes, France. 3. Department of Urology, APHP-Pitié-Salpétrière Hospital, Sorbonne Université, Paris, France. 4. Inserm U1179, UFR Des Sciences de la Santé, University of Versailles Saint-Quentin, Montigny-le-Bretonneux, France. 5. Neuro-Uro-Andrology Hospital Universitaire R.Poincare, AP-HP, 104 bvd R. Poincare, 92380, Garches, France. charles.jsn@free.fr. 6. Inserm U1179, UFR Des Sciences de la Santé, University of Versailles Saint-Quentin, Montigny-le-Bretonneux, France. charles.jsn@free.fr.
Abstract
PURPOSE: This study aimed to determine the long-term effectiveness of augmentation ileocystoplasty (AI) associated with supra-trigonal cystectomy on clinical and urodynamic variables, and the safety of the intervention in individuals with spinal cord injury (SCI). MATERIALS AND METHODS: Single-center, retrospective study of all patients with SCI who underwent AI with supra-trigonal cystectomy from January 1994, with a follow-up of more than 8 years. The primary outcome was the sustained long-term effectiveness of AI with supra-trigonal cystectomy on clinical and urodynamic variables. The secondary outcome was the long-term safety of this procedure. RESULTS: We included 77 patients: 57% were female, mean (SD) age was 52.0 (13.0) years, 77% had paraplegia, and median time since onset was 25.0 [19; 30] years. Long-term success rate (evaluated 13 [10; 15] years post AI) was 93.5% for urodynamic parameters and 76.6% for urinary incontinence. Results of the short- and long-term post-AI assessments did not differ for any urodynamic or clinical variables. Bladder lithiasis occurred in 20.5% of cases and ≥ 1 febrile urinary tract infection occurred in 55.8%, mostly within the first 2 years of follow-up. No cases of bladder cancer were diagnosed. CONCLUSION: AI associated with supra-trigonal cystectomy in patients with SCI is safe and effective in both the short term and long term. Regular urodynamic assessment is not necessary in clinically stable patients with low bladder risk; however, close monitoring is important because of the risk of urological complications.
PURPOSE: This study aimed to determine the long-term effectiveness of augmentation ileocystoplasty (AI) associated with supra-trigonal cystectomy on clinical and urodynamic variables, and the safety of the intervention in individuals with spinal cord injury (SCI). MATERIALS AND METHODS: Single-center, retrospective study of all patients with SCI who underwent AI with supra-trigonal cystectomy from January 1994, with a follow-up of more than 8 years. The primary outcome was the sustained long-term effectiveness of AI with supra-trigonal cystectomy on clinical and urodynamic variables. The secondary outcome was the long-term safety of this procedure. RESULTS: We included 77 patients: 57% were female, mean (SD) age was 52.0 (13.0) years, 77% had paraplegia, and median time since onset was 25.0 [19; 30] years. Long-term success rate (evaluated 13 [10; 15] years post AI) was 93.5% for urodynamic parameters and 76.6% for urinary incontinence. Results of the short- and long-term post-AI assessments did not differ for any urodynamic or clinical variables. Bladder lithiasis occurred in 20.5% of cases and ≥ 1 febrile urinary tract infection occurred in 55.8%, mostly within the first 2 years of follow-up. No cases of bladder cancer were diagnosed. CONCLUSION: AI associated with supra-trigonal cystectomy in patients with SCI is safe and effective in both the short term and long term. Regular urodynamic assessment is not necessary in clinically stable patients with low bladder risk; however, close monitoring is important because of the risk of urological complications.
Authors: Jerzy B Gajewski; Brigitte Schurch; Rizwan Hamid; Márcio Averbeck; Ryuji Sakakibara; Enrico F Agrò; Tamara Dickinson; Christopher K Payne; Marcus J Drake; Bernie T Haylen Journal: Neurourol Urodyn Date: 2017-11-17 Impact factor: 2.696
Authors: Jeremy B Myers; Sara M Lenherr; John T Stoffel; Sean P Elliott; Angela P Presson; Chong Zhang; Jeffery Rosenbluth; Amitabh Jha; Darshan P Patel; Blayne Welk Journal: J Urol Date: 2019-08-08 Impact factor: 7.450